John Bushweller
Affiliations: | University of Virginia, Charlottesville, VA |
Area:
General Biophysics, Cell BiologyGoogle:
"John Bushweller"Mean distance: (not calculated yet)
Children
Sign in to add trainee| Yizhou Liu | grad student | 2006 | UVA |
| Stephen M. Lukasik | grad student | 2006 | UVA |
| Yunpeng Zhou | grad student | 2008 | UVA |
| Takeshi A. Corpora | grad student | 2009 | UVA |
| Benjamin I. Leach | grad student | 2011 | UVA |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kalmode HP, Podsiadly I, Kabra A, et al. (2022) Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation. Acs Medicinal Chemistry Letters. 13: 1363-1369 |
| Kim KB, Kabra A, Kim DW, et al. (2022) KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer. Science Advances. 8: eabl4618 |
| Kabra A, Bushweller J. (2021) The intrinsically disordered proteins MLLT3 (AF9) and MLLT1 (ENL) - multimodal transcriptional switches with roles in normal hematopoiesis, MLL fusion leukemia, and kidney cancer. Journal of Molecular Biology. 167117 |
| Schmidt CR, Achille NJ, Kuntimaddi A, et al. (2020) BCOR Binding to MLL-AF9 Is Essential for Leukemia via Altered EYA1, SIX, and MYC Activity. Blood Cancer Discovery. 1: 162-177 |
| Deltcheva E, Wray J, James C, et al. (2019) EXPLOITING CBF DEPENDENCY IN B-ACUTE LYMPHOBLASTIC LEUKAEMIA AS A NOVEL THERAPEUTIC APPROACH Experimental Hematology. 76: S63 |
| Zhou Y, Bushweller JH. (2018) Solution structure and elevator mechanism of the membrane electron transporter CcdA. Nature Structural & Molecular Biology |
| Schmidt C, Kuntimaddi A, Leach B, et al. (2018) Solution NMR structure of BCoR in complex with AF9 (BCoR-AF9) Journal of Back and Musculoskeletal Rehabilitation |
| Bushweller JH, Schmidt C, Achille N, et al. (2018) Direct Binding of BCOR, but Not CBX8, to MLL-AF9 Is Essential for MLL-AF9 Leukemia Via Regulation of the EYA1/SIX1 Gene Network Blood. 132: 1316-1316 |
| Oo ZM, Illendula A, Grembecka J, et al. (2017) A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells. Leukemia & Lymphoma. 1-13 |
| Illendula A, Gilmour J, Grembecka J, et al. (2017) Corrigendum to: "Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers" [EBioMedicine 8 (2016) 117-131]. Ebiomedicine |